These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 18289149)

  • 1. Six-month paroxetine treatment of premenstrual dysphoric disorder: continuous versus intermittent treatment protocols.
    Wu KY; Liu CY; Hsiao MC
    Psychiatry Clin Neurosci; 2008 Feb; 62(1):109-14. PubMed ID: 18289149
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Luteal phase treatment of premenstrual dysphoric disorder improves symptoms that continue into the postmenstrual phase.
    Yonkers KA; Pearlstein T; Fayyad R; Gillespie JA
    J Affect Disord; 2005 Apr; 85(3):317-21. PubMed ID: 15780701
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A naturalistic study of paroxetine in premenstrual syndrome: efficacy and side-effects during ten cycles of treatment.
    Sundblad C; Wikander I; Andersch B; Eriksson E
    Eur Neuropsychopharmacol; 1997 Aug; 7(3):201-6. PubMed ID: 9213079
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Paroxetine treatment of mood disorders in women: premenstrual dysphoric disorder and hot flashes.
    Yonkers KA
    Psychopharmacol Bull; 2003; 37 Suppl 1():135-47. PubMed ID: 14566208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fluvoxamine for premenstrual dysphoric disorder: a pilot study.
    Freeman EW; Rickels K; Sondheimer SJ
    J Clin Psychiatry; 1996; 57 Suppl 8():56-9; discussion 60. PubMed ID: 8698682
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patterns of mood changes throughout the reproductive cycle in healthy women without premenstrual dysphoric disorders.
    Gonda X; Telek T; Juhász G; Lazary J; Vargha A; Bagdy G
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Dec; 32(8):1782-8. PubMed ID: 18721843
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of a unique oral contraceptive (Yasmin) in the management of premenstrual dysphoric disorder.
    Freeman EW
    Eur J Contracept Reprod Health Care; 2002 Dec; 7 Suppl 3():27-34; discussion 42-3. PubMed ID: 12659404
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnosis and treatment of premenstrual dysphoric disorder: an update.
    Steiner M; Born L
    Int Clin Psychopharmacol; 2000 Nov; 15 Suppl 3():S5-17. PubMed ID: 11195269
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paroxetine controlled release.
    Bang LM; Keating GM
    CNS Drugs; 2004; 18(6):355-64; discussion 365-6. PubMed ID: 15089103
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and tolerability of premenstrual use of venlafaxine (flexible dose) in the treatment of premenstrual dysphoric disorder.
    Cohen LS; Soares CN; Lyster A; Cassano P; Brandes M; Leblanc GA
    J Clin Psychopharmacol; 2004 Oct; 24(5):540-3. PubMed ID: 15349012
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Psychological aspects of premenstrual syndrome.
    Indusekhar R; Usman SB; O'Brien S
    Best Pract Res Clin Obstet Gynaecol; 2007 Apr; 21(2):207-20. PubMed ID: 17175199
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Weekly luteal-phase dosing with enteric-coated fluoxetine 90 mg in premenstrual dysphoric disorder: a randomized, double-blind, placebo-controlled clinical trial.
    Miner C; Brown E; McCray S; Gonzales J; Wohlreich M
    Clin Ther; 2002 Mar; 24(3):417-33. PubMed ID: 11952025
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Placebo-controlled trial comparing intermittent and continuous paroxetine in premenstrual dysphoric disorder.
    Landén M; Nissbrandt H; Allgulander C; Sörvik K; Ysander C; Eriksson E
    Neuropsychopharmacology; 2007 Jan; 32(1):153-61. PubMed ID: 17035933
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of paroxetine in the treatment of obsessive-compulsive disorders.
    Kamijima K; Aoki M
    Expert Rev Neurother; 2006 Jul; 6(7):945-56. PubMed ID: 16831110
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gonadotropin-releasing hormone agonist in the treatment of premenstrual symptoms with and without ongoing dysphoria: a controlled study.
    Freeman EW; Sondheimer SJ; Rickels K
    Psychopharmacol Bull; 1997; 33(2):303-9. PubMed ID: 9230648
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of kamishoyosan for premenstrual dysphoric disorder: open-labeled pilot study.
    Yamada K; Kanba S
    Psychiatry Clin Neurosci; 2007 Jun; 61(3):323-5. PubMed ID: 17472603
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of intermittent, luteal phase sertraline treatment of premenstrual dysphoric disorder.
    Halbreich U; Bergeron R; Yonkers KA; Freeman E; Stout AL; Cohen L
    Obstet Gynecol; 2002 Dec; 100(6):1219-29. PubMed ID: 12468166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Menstrually related symptom changes in women with treatment-responsive bipolar disorder.
    Karadag F; Akdeniz F; Erten E; Pirildar S; Yucel B; Polat A; Atmaca M
    Bipolar Disord; 2004 Jun; 6(3):253-9. PubMed ID: 15117404
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Luteal phase administration of paroxetine for the treatment of premenstrual dysphoric disorder: a randomized, double-blind, placebo-controlled trial in Canadian women.
    Steiner M; Ravindran AV; LeMelledo JM; Carter D; Huang JO; Anonychuk AM; Simpson SD
    J Clin Psychiatry; 2008 Jun; 69(6):991-8. PubMed ID: 18517289
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Symptom-onset treatment for women with premenstrual dysphoric disorder.
    Yonkers KA; Holthausen GA; Poschman K; Howell HB
    J Clin Psychopharmacol; 2006 Apr; 26(2):198-202. PubMed ID: 16633152
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.